Sequenom (SQNM) Launches Noninvasive MaterniT21 LDT for Downs Syndrome
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Join SI Premium – FREE
Sequenom, Inc. (Nasdaq: SQNM), reports its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), launched its noninvasive proprietary MaterniT21 laboratory developed test (LDT). The MaterniT21 LDT detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome. The test is now available to physicians upon request in 20 major metropolitan regions across the United States.
The MaterniT21 test is indicated for use in pregnant women at high-risk for carrying a fetus with Down syndrome and can accurately test maternal blood as early as 10 weeks of gestation. In the United States, there are an estimated 750,000 such high-risk pregnancies each year.
The MaterniT21 test is indicated for use in pregnant women at high-risk for carrying a fetus with Down syndrome and can accurately test maternal blood as early as 10 weeks of gestation. In the United States, there are an estimated 750,000 such high-risk pregnancies each year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Saba Capital funds reapprove merger plan targeting Q4 2026 close
- Blue Moon Metals cleared to build at Nevada tungsten project
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
